Tuesday, March 23, 2010

Ruxolitinib


Pronunciation: RUX-oh-LI-ti-nib
Generic Name: Ruxolitinib
Brand Name: Jakafi


Ruxolitinib is used for:

Treating certain types of myelofibrosis. It may also be used for other conditions as determined by your doctor.


Ruxolitinib is a kinase inhibitor. It works by blocking certain substances (JAK1 and JAK2) that are involved in myelofibrosis.


Do NOT use Ruxolitinib if:


  • you are allergic to any ingredient in Ruxolitinib

  • you have a serious infection

  • you have certain severe kidney problems

Contact your doctor or health care provider right away if any of these apply to you.



Before using Ruxolitinib:


Some medical conditions may interact with Ruxolitinib. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have anemia, low blood platelet levels, or low white blood cell counts

  • if you have an infection (bacterial, viral, fungal, or mycobacterial) or a history of infection that keeps coming back

  • if you are on dialysis or have a history of liver or kidney problems

  • if you are not able to take Ruxolitinib by mouth

Some MEDICINES MAY INTERACT with Ruxolitinib. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Azole antifungals (eg, itraconazole, ketoconazole), conivaptan, macrolide antibiotics (eg, clarithromycin), mibefradil, nefazodone, protease inhibitors (eg, boceprevir, ritonavir), or telithromycin because they may increase the risk of Ruxolitinib's side effects

  • Rifampin because it may decrease Ruxolitinib's effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Ruxolitinib may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Ruxolitinib:


Use Ruxolitinib as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • An extra patient leaflet is available with Ruxolitinib. Talk to your pharmacist if you have questions about this information.

  • Take Ruxolitinib by mouth with or without food.

  • Do not eat grapefruit or drink grapefruit juice while you use Ruxolitinib without first checking with your doctor.

  • Do not suddenly stop taking Ruxolitinib. If you need to stop Ruxolitinib, your doctor may gradually lower your dose.

  • Continue to take Ruxolitinib even if you feel well. Do not miss any doses.

  • If you miss a dose of Ruxolitinib, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Ruxolitinib.



Important safety information:


  • Ruxolitinib may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Ruxolitinib with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Do not change your dose or stop taking Ruxolitinib without checking with your doctor.

  • If you are on dialysis, do not take your dose of Ruxolitinib before your dialysis treatment. Take your dose after your dialysis treatment is finished. Check with your doctor if you have any questions.

  • Ruxolitinib may lower the ability of your body to fight infection, including shingles. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, chills, or increased or painful urination. Symptoms of shingles may include painful skin rash or blisters.

  • Ruxolitinib may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.

  • Ruxolitinib is not a cure for myelofibrosis. Signs and symptoms are expected to return if Ruxolitinib is stopped. Discuss any questions or concerns with your doctor.

  • Lab tests, including complete blood cell counts, may be performed while you use Ruxolitinib. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Ruxolitinib should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Ruxolitinib while you are pregnant. It is not known if Ruxolitinib is found in breast milk. Do not breast-feed while taking Ruxolitinib.


Possible side effects of Ruxolitinib:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Dizziness; gas; headache; weight gain.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); painful skin rash or blisters; shortness of breath; symptoms of infection (eg, fever, chills, persistent sore throat, increased or painful urination, nausea or vomiting); unusual bruising or bleeding; unusual tiredness or weakness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Ruxolitinib side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include symptoms of infection (eg, fever, chills, persistent sore throat, increased or painful urination); unusual bruising or bleeding; unusual tiredness or weakness.


Proper storage of Ruxolitinib:

Store Ruxolitinib at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Ruxolitinib out of the reach of children and away from pets.


General information:


  • If you have any questions about Ruxolitinib, please talk with your doctor, pharmacist, or other health care provider.

  • Ruxolitinib is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine

This information is a summary only. It does not contain all information about Ruxolitinib. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Ruxolitinib resources


  • Ruxolitinib Side Effects (in more detail)
  • Ruxolitinib Use in Pregnancy & Breastfeeding
  • Ruxolitinib Drug Interactions
  • Ruxolitinib Support Group
  • 0 Reviews for Ruxolitinib - Add your own review/rating


  • Ruxolitinib Professional Patient Advice (Wolters Kluwer)

  • ruxolitinib Advanced Consumer (Micromedex) - Includes Dosage Information

  • Jakafi Prescribing Information (FDA)

  • Jakafi Consumer Overview



Compare Ruxolitinib with other medications


  • Myelofibrosis
  • Myeloproliferative Disorders

Monday, March 22, 2010

Airnurse




Airnurse may be available in the countries listed below.


Ingredient matches for Airnurse



Acyclovir

Aciclovir is reported as an ingredient of Airnurse in the following countries:


  • Japan

International Drug Name Search

Sunday, March 21, 2010

Diprolene Cream


Pronunciation: bay-tah-METH-uh-zone die-PRO-pee-oh-nate
Generic Name: Betamethasone Dipropionate (Augmented)
Brand Name: Diprolene


Diprolene Cream is used for:

Reducing itching, redness, and swelling associated with many skin conditions.


Diprolene Cream is a topical corticosteroid. It works by depressing the formation, release, and activity of different cells and chemicals that cause swelling, redness, and itching.


Do NOT use Diprolene Cream if:


  • you are allergic to any ingredient in Diprolene Cream or to another corticosteroid (eg, prednisone)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Diprolene Cream:


Some medical conditions may interact with Diprolene Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have thinning of the skin, a skin infection, tuberculosis, chickenpox, shingles, measles, a positive TB skin test, or have recently been vaccinated

Some MEDICINES MAY INTERACT with Diprolene Cream. Because little, if any, of Diprolene Cream is absorbed into the blood, the risk of it interacting with another medicine is low.


Ask your health care provider if Diprolene Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Diprolene Cream:


Use Diprolene Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Apply a small amount of medicine to the affected area. Gently rub the medicine in until it is evenly distributed. Wash your hands after applying Diprolene Cream, unless your hands are part of the treated area. Do not apply Diprolene Cream to the face, groin, or armpit unless otherwise directed by your doctor.

  • Do not cover the treating area with bandages, wrappings, or other dressings unless advised to do so by your health care provider.

  • If you miss a dose of Diprolene Cream, apply it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Diprolene Cream.



Important safety information:


  • Diprolene Cream is for external use only. Avoid contact with the eyes. If you get Diprolene Cream in your eyes, immediately flush with cool tap water.

  • If your symptoms do not get better within 2 weeks or if they get worse, check with your doctor.

  • Do not use Diprolene Cream for other skin conditions at a later time.

  • Diprolene Cream has a corticosteroid in it. Before you start any new medicine, check the label to see if it has a corticosteroid in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Do not use Diprolene Cream to treat the diaper area of a child, unless directed otherwise by your doctor.

  • Check with your doctor before you have any vaccinations while you are using Diprolene Cream.

  • Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while they use Diprolene Cream.

  • Diprolene Cream should not be used in CHILDREN younger than 13 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Diprolene Cream while you are pregnant. It is not known if Diprolene Cream is found in breast milk. If you are or will be breast-feeding while you use Diprolene Cream, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Diprolene Cream:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Dry skin; mild, temporary stinging when applied.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne-like rash; burning, cracking, irritation, or peeling not present before you began using Diprolene Cream; excessive hair growth; inflamed hair follicles; inflammation around the mouth; muscle weakness; thinning, softening, or discoloration of the skin; unusual weight gain, especially in the face.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Diprolene side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include increased thirst or urination; muscle weakness; unusual weight gain, especially in the face.


Proper storage of Diprolene Cream:

Store Diprolene Cream at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Do not freeze. Store away from heat, moisture, and light. Keep Diprolene Cream out of the reach of children and away from pets.


General information:


  • If you have any questions about Diprolene Cream, please talk with your doctor, pharmacist, or other health care provider.

  • Diprolene Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Diprolene Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Diprolene resources


  • Diprolene Side Effects (in more detail)
  • Diprolene Use in Pregnancy & Breastfeeding
  • Diprolene Drug Interactions
  • Diprolene Support Group
  • 2 Reviews for Diprolene - Add your own review/rating


Compare Diprolene with other medications


  • Atopic Dermatitis
  • Dermatitis
  • Dermatological Disorders
  • Lichen Planus
  • Lichen Sclerosus

Tuesday, March 16, 2010

Famphur




In some countries, this medicine may only be approved for veterinary use.

CAS registry number (Chemical Abstracts Service)

0000052-85-7

Chemical Formula

C10-H16-N-O5-P-S2

Molecular Weight

325

Therapeutic Category

Insecticide

Chemical Names

O,O-dimethyl-O,p-(dimethylsulfamoyl)phenyl phosphorothioate

p-hydroxy-N,N-dimethylbenzenesulfonamide ester with phosphorothioic aicd O,O-dimethyl ester

Phosphorothioic acid O-[4-[(dimethylamino)sulfonyl]phenyl] O,O-dimethyl ester

Foreign Names

  • Famphur (German)
  • Famfur (Spanish)

Generic Names

  • AC 38023 (IS)
  • AI3-25644 (IS)
  • American cyanamid CL-38023 (IS)
  • BRN 2224254 (IS)
  • Caswell No. 456D (IS)
  • CL-38023 (IS)
  • EINECS 200-154-0 (IS)
  • ENT 25644 (IS)
  • EPA Pesticide Chemical Code 059901 (IS)
  • Famphos (IS)
  • HSDB 6048 (IS)
  • RCRA waste number P097 (IS)
  • Warbex (IS)

Brand Names

  • Bo Ana (veterinary use)
    Schering-Plough Animal Health, United States


  • Famix (veterinary use)
    Schering-Plough Animal Health, United States


  • Purina (veterinary use)
    Virbac, United States


  • Tramisol (Famphur and Levamisole (veterinary use))
    Schering-Plough Animal Health, United States


  • Warbex (veterinary use)
    Schering-Plough Animal Health, United States

International Drug Name Search

Glossary

ISInofficial Synonym

Click for further information on drug naming conventions and International Nonproprietary Names.

Sunday, March 14, 2010

Citin




Citin may be available in the countries listed below.


Ingredient matches for Citin



Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Citin in the following countries:


  • Bangladesh

International Drug Name Search

Saturday, March 13, 2010

Tiopronin




In the US, Tiopronin (tiopronin systemic) is a member of the drug class miscellaneous genitourinary tract agents and is used to treat Cystinuria.

US matches:

  • Tiopronin

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

R05CB12

CAS registry number (Chemical Abstracts Service)

0001953-02-2

Chemical Formula

C5-H9-N-O3-S

Molecular Weight

163

Therapeutic Categories

Mucolytic agent

Antidote: Chelating agent

Hepatoprotective agent

Chemical Name

Glycine, N-(2-mercapto-1-oxopropyl)-

Foreign Names

  • Tioproninum (Latin)
  • Tiopronin (German)
  • Tiopronine (French)
  • Tiopronina (Spanish)

Generic Names

  • Tiopronin (OS: JAN)
  • Tiopronina (OS: DCIT)
  • Tiopronine (OS: DCF)
  • SF 522 (IS)

Brand Names

  • Acadione
    Sanofi-Aventis, France


  • Captimer
    MIT Gesundheit, Germany


  • Stargen
    Shyh Dar, Taiwan


  • Thiola
    Coop. Farm., Italy; Mission, United States; Mylan Pharmaceutical, Japan


  • Thiosol
    Coop. Farm., Italy

International Drug Name Search

Glossary

DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Friday, March 12, 2010

Dilatrate-SR


Dilatrate-SR is a brand name of isosorbide dinitrate, approved by the FDA in the following formulation(s):


DILATRATE-SR (isosorbide dinitrate - capsule, extended release; oral)



  • Manufacturer: SCHWARZ PHARMA

    Approval date: September 2, 1988

    Strength(s): 40MG [RLD]

Has a generic version of Dilatrate-SR been approved?


No. There is currently no therapeutically equivalent version of Dilatrate-SR available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilatrate-SR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Dilatrate-SR.

See also...

  • Dilatrate-SR Consumer Information (Wolters Kluwer)
  • Dilatrate-SR Consumer Information (Cerner Multum)
  • Dilatrate-SR Advanced Consumer Information (Micromedex)
  • Isosorbide Dinitrate Consumer Information (Wolters Kluwer)
  • Isosorbide Dinitrate Extended-Release Consumer Information (Wolters Kluwer)
  • Isosorbide dinitrate Consumer Information (Cerner Multum)
  • Apo-Isdn Advanced Consumer Information (Micromedex)
  • Isosorbide dinitrate Oral, Sublingual Advanced Consumer Information (Micromedex)

Thursday, March 11, 2010

Hydroxyzine




In some countries, this medicine may only be approved for veterinary use.


In the US, Hydroxyzine (hydroxyzine systemic) is a member of the following drug classes: antihistamines, miscellaneous anxiolytics, sedatives and hypnotics and is used to treat Allergic Urticaria, Anxiety, Nausea/Vomiting, Pain, Pruritus and Sedation.

US matches:

  • Hydroxyzine

  • Hydroxyzine Capsules

  • Hydroxyzine Suspension

  • Hydroxyzine Syrup

  • Hydroxyzine Hydrochloride

  • Hydroxyzine Pamoate

  • Hydroxyzine Oral Solution

  • Hydroxyzine Tablets

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N05BB01

CAS registry number (Chemical Abstracts Service)

0000068-88-2

Chemical Formula

C21-H27-Cl-N2-O2

Molecular Weight

374

Therapeutic Category

Anxiolytic agent

Chemical Name

Ethanol, 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-

Foreign Names

  • Hydroxyzinum (Latin)
  • Hydroxyzin (German)
  • Hydroxyzine (French)
  • Hidroxizina (Spanish)

Generic Names

  • Hydroxyzine (OS: DCF, BAN)
  • Idroxizina (OS: DCIT)
  • UCB 4492 (IS: UCB)
  • Hydroxyzine Pamoate (OS: JAN)
  • Hydroxyzine Pamoate (PH: USP 32, JP XIV)
  • Hydroxyzine Hydrochloride (OS: BANM)
  • Hydroxyzine dihydrochloride (IS)
  • Hydroxyzindihydrochlorid (PH: Ph. Eur. 6)
  • Hydroxyzine (chlorhydrate d') (PH: Ph. Eur. 6)
  • Hydroxyzine Hydrochloride (PH: BP 2010, Ph. Eur. 6, USP 32, JP XIV)
  • Hydroxyzini hydrochloridum (PH: Ph. Eur. 6)

Brand Names

  • Apo-Hydroxyzine
    Apotex, Vietnam


  • Atarax
    IBN, Tunisia; UCB, Bulgaria; UCB, Tunisia


  • Dormirex
    Lafrancol, Guatemala


  • Hidroxicina Genfar
    Genfar, Colombia; Genfar, Ecuador


  • Hydroxyzine HCL
    Mutual, United States


  • Hytis
    General Pharma, Bangladesh


  • Qualidrozine
    Quality, Hong Kong


  • Atarax-P
    Pfizer, Japan


  • Hatanazin
    Nisshin Seiyaku - Yamagata, Japan


  • Hyderax
    HLB, Argentina


  • Hydroxyzine Pamoate
    Sandoz, United States; Teva USA, United States; Watson, United States


  • Vistaril
    Pfizer, Taiwan; Pfizer, United States


  • AH 3
    UCB, Germany


  • Anx
    Econo Med, United States


  • Apo-Hydroxyzine
    Apotex, Canada; Apotex, Hong Kong; Apotex, Singapore


  • Atarax
    ACI, Bangladesh; Alfa, Peru; Alliance, United Arab Emirates; Alliance, Egypt; Alliance, United Kingdom; Alliance, Iraq; Alliance, Iran; Alliance, Jordan; Alliance, Kuwait; Alliance, Lebanon; Alliance, Qatar; Alliance, Saudi Arabia; Alliance, Syria; Alliance, Yemen; Pfizer, Guyana; Pfizer, Japan; Pfizer, United States; Solvay, Russian Federation; UCB, Austria; UCB, Belgium; UCB, Burkina Faso; UCB, Bahrain; UCB, Burundi; UCB, Benin; UCB, Central African Republic; UCB, Congo; UCB, Cote D'ivoire; UCB, Cameroon; UCB, Czech Republic; UCB, Germany; UCB, Denmark; UCB, Algeria; UCB, Spain; UCB, Finland; UCB, France; UCB, Gabon; UCB, Georgia; UCB, Guinea; UCB, Greece; UCB, Hong Kong; UCB, Hungary; UCB, India; UCB, Iceland; UCB, Italy; UCB, Luxembourg; UCB, Madagascar; UCB, Mali; UCB, Mauritania; UCB, Mauritius; UCB, Mexico; UCB, Malaysia; UCB, Niger; UCB, Netherlands; UCB, Norway; UCB, Oman; UCB, Poland; UCB, Portugal; UCB, Sweden; UCB, Singapore; UCB, Senegal; UCB, Chad; UCB, Togo; UCB, Thailand; UCB, Turkey; UCB, Taiwan; UCB, Taiwan; UCB, Zaire; UCB Pharma, Malta; UCB-Pharma, Switzerland


  • Atarax (veterinary use)
    Pfizer Animal Health, United Kingdom


  • Ataraxone
    Lazar, Argentina


  • Atarax-P
    Pfizer, Japan


  • Aterax
    UCB, South Africa


  • Bestalin
    Lapi Laboratories, Indonesia


  • Cedar
    Psipharma, Colombia


  • Dalun
    Medipharm, Chile


  • Disron
    Nagase Iyakuhin, Japan


  • Fasarax
    Prater, Chile


  • Fedox
    Mediderm, Chile


  • Hiderax
    Lafrancol, Colombia


  • Hidroxicina La Santé
    La Santé, Colombia


  • Hidroxizin
    Sicomed, Romania


  • Histacalmine (Hydroxyzine and Chlorphenamine (veterinary use))
    Virbac, France


  • Histaderm (Hydroxyzine and Chlorphenamine (veterinary use))
    Sogeval, France


  • Hydroxyzine Europharm
    Europharm, Hong Kong


  • Hydroxyzine HCL
    Actavis, United States; Amneal, United States; Andapharm, United States; Hetero, United States; Hi-Tech, United States; InvaGen, United States; KVK Tech, United States; Luitpold, United States; Morton Grove, United States; Northstar, United States; Pliva, United States; Sandoz, United States; Sun, United States; Teva USA, United States; UCB, Netherlands; Vintage, United States; Watson, United States


  • Hydroxyzine Renaudin
    Renaudin, France


  • Hydroxyzinum
    ICN, Lithuania; ICN, Poland; Pliva, Poland; Polon, Poland


  • Iremofar
    Uni-Pharma, Greece


  • Iterax
    UCB, Indonesia; UCB, Philippines


  • Neucalm
    Legere, United States


  • Neurax
    Merck Generics, South Africa


  • Neurolax
    Actavis, Georgia


  • Otarex
    Teva, Israel


  • Ucerax
    UCB, United Arab Emirates; UCB, Bahrain; UCB, Egypt; UCB, Ireland; UCB, Iraq; UCB, Iran; UCB, Jordan; UCB, Kuwait; UCB, Lebanon; UCB, Oman; UCB, Qatar; UCB, Saudi Arabia; UCB, Syria; UCB, Yemen; UCB Pharma, United Kingdom


  • Ucerax (veterinary use)
    UCB, United Kingdom


  • Vetaraxoid (Hydroxyzine and Prednisolone (veterinary use))
    Pfizer, Austria; Pfizer Animal Health, Finland


  • Vistaril
    Pfizer, United States

International Drug Name Search

Glossary

BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.